依维莫司治疗晚期乳腺癌的临床用药情况调查  

Investigation of clinical application of everolimus in the treatment of advanced breast cancer

作　　者：曹明楠 潘晨 赵志刚[1] CAO Ming-nan;PAN Chen;ZHAO Zhi-gang(Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 10070,China;Department of Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100070 [2]首都医科大学附属北京友谊医院药剂科,北京100050

出　　处：《临床药物治疗杂志》2024年第1期26-30,共5页Clinical Medication Journal

基　　金：国家卫健委医院管理研究所项目(YLZLXZ23G014)。

摘　　要：目的对依维莫司用于晚期乳腺癌的处方/医嘱进行药物应用调查,分析依维莫司的用药现状,以促进临床合理用药。方法收集2018年1月至2022年2月13家医疗机构依维莫司治疗晚期乳腺癌的处方/医嘱,对其用法用量、用药时长、合并用药及日均剂量进行分析。结果共纳入晚期乳腺癌患者2517例,分别有12.7%、47.3%和4.0%的患者依维莫司采用了10.0 mg qd、5.0 mg qd及2.5 mg qd的用药方式;依维莫司主要与芳香胺酶抑制剂(AI)及雌激素受体(ER)拮抗剂合用,有42.7%的患者合用了依西美坦。联合用药组依维莫司的日均用量低于未联用药物组,其中合并依西美坦组依维莫司日均用量为6.0 mg。结论依维莫司多采用联合用药模式,其日均剂量明显低于说明书推荐剂量,致使日均费用远低于预期,相关应用具有一定的循证证据支持。Objective To investigate and analyze the prescriptions/orders of everolimus for patients with advanced breast cancer in order to promote further rational application.Methods Relevant prescriptions/medical orders from 13 medical institu⁃tions from January 2018 to February 2022 were collected,and the dosage,medication duration,combined medication,and average daily dose were analyzed.Results A total of 2517 patients with advanced breast cancer were included.12.7%,47.3%and 4.0%of the investigated patients were given everolimusat 10.0 mg qd,5.0 mg qd,and 2.5 mg qd,respectively.Everolimus was mainly used in combination with aromatic amine enzyme inhibitors(AIs)and estrogen receptor(ER)antago⁃nists,and 42.7%of the patients chose exemestane.The average daily dose of everolimus in the combination group was lower than that in the non-combination group,and in specific,the average daily dose of everolimus in the combined exemestane group was 6.0 mg.Conclusion Everolimus is usually adopted by combined use,and the average daily dose of everolimus is significantly lower than the recommended dose in the manual,resulting in the daily average cost far lower than expected,and the clinical application has evidence-based support.

关 键 词：依维莫司 晚期乳腺癌 内分泌治疗 联合用药 日均剂量 

分 类 号：R979.19[医药卫生—药品] R969.3[医药卫生—药学]